What is SignalRank?
SignalRank is a predictive model rather than a traditional sourcing database, built to estimate a startup's odds of graduating from Series A to Series B. It packages that prediction as an index-fund product rather than a direct software subscription, which shapes everything about how it is bought and used. The lead time is forward-looking: it scores companies that are already post-Series A, projecting their later-stage trajectory rather than flagging early-stage opportunities. Its published methodology is peer-reviewed, and its signal for Series-B graduation odds is among the strongest in the market, which makes it useful for late-stage thesis validation and for institutions that want systematic, data-driven exposure to the growth-stage segment. The methodology itself is available publicly even though the product is not a conventional SaaS subscription. The limitations are stage-bound. It is of no use for pre-seed or seed sourcing, which is a different problem entirely, and it is not a deal-sourcing tool in the conventional sense. There is no individual-investor SaaS access, so a solo angel cannot adopt it as a workflow. Its output is a score, not a list of companies to contact. It belongs in a specific lane: institutional, growth-stage, and passive-index oriented, where it is genuinely differentiated but narrow.
Best for: Best for late-stage investors validating Series-B graduation odds and seeking systematic data-driven growth-stage index exposure.
What is PitchBook?
PitchBook is the institutional gold standard for private-markets data, serving LPs, GPs, investment banks, and analysts with deep coverage of fund performance, secondaries, M&A, and the wider private capital landscape. Its data model is curated and post-event, assembled by a large analyst organisation into benchmarks, rankings, and reference datasets that the industry treats as authoritative. The platform is best understood as an analytical and benchmarking layer rather than a sourcing tool: it tells you what has happened across funds and companies, with the depth and reliability that institutions require for underwriting, LP reporting, and thesis work. Its limitations follow directly from that design. It is enterprise-priced at about twenty thousand dollars a year and up, which puts it out of reach for solo investors and angels, and it offers no free tier. It lags by design, recording events after they occur rather than predicting them. Its interface and workflow are built for analysts, not operators, so it sits naturally at the research end of the stack rather than the discovery end. Its buyers are institutions with analysts on staff, and it is the reference layer against which other private-markets data is judged. It is a reference system, not an early-signal engine, and it is almost always deployed alongside sourcing tools rather than as a substitute for them.
Best for: Best for institutional LPs, GPs, and bankers who need gold-standard fund performance, M&A, and private-markets benchmarks.